0
Eloxx Pharmaceuticals, Inc. Banner Image

Eloxx Pharmaceuticals, Inc. has reached its limit for free report views

Work for Eloxx Pharmaceuticals, Inc.? Upgrade Your Profile and unlock all your annual reports.

Eloxx Pharmaceuticals, Inc.

  • Ticker ELOX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Eloxx Pharmaceuticals, Inc. Logo Image
  • 11-50 Employees
  • Based in Waltham, Massachusetts
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with prematureMore stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins
Eloxx Pharmaceuticals, Inc.

Most Recent Annual Report

Eloxx Pharmaceuticals, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Eloxx Pharmaceuticals, Inc. has reached its limit for free report views.

Older/Archived Annual Reports